Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats

European Journal of Pharmacology

Volumn 614, Issue 1-3, 2009, Pages 70-76

  Nishida, Masahiro ^a   Hasegawa, Youichi ^a   Tanida, Izumi ^a   Nakagawa, Erika ^a   Inaji, Haruka ^a   Ohkita, Mamoru ^a   Matsumura, Yasuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Endothelin 1; Female rat; Monocrotaline; Ovariectomy; Pulmonary hypertension; Raloxifene

Indexed keywords

ENDOTHELIN 1; MONOCROTALINE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL WALL THICKENING; ARTERY MEDIA; ARTICLE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE VOLUME; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE VOLUME; INHIBITION KINETICS; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; ENDOTHELIN-1; FEMALE; HEART VENTRICLES; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MONOCROTALINE; ORGAN SIZE; OVARIECTOMY; PULMONARY ARTERY; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SUBSTRATE SPECIFICITY; TIME FACTORS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 67349250518     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.016     Document Type: Article

References (50)

1. Ahn B.H., Park H.K., Cho H.G., Lee H.A., Lee Y.M., Yang E.K., and Lee W.J. Estrogen and enalapril attenuate the development of right ventricular hypertrophy induced by monocrotaline in ovariectomized rats. J. Korean Med. Sci. 18 (2003) 641-648
2. Arias-Loza P.A., Jazbutyte V., and Pelzer T. Genetic and pharmacological strategies to determine the function of estrogen receptor α and estrogen receptor β in the cardiovascular system. Gen. Med. 5 (2008) S34-S45
3. Ball L.J., Levy N., Zhao X., Griffin G., Tagliaferri M., Cohen I., Ricke W.A., Speed T.P., Firestone G.L., and Leitman D.C. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements. Mol. Cell. Endocrinol. 299 (2009) 204-211
4. Beretta L., Caronni M., Origgi L., Ponti A., Santaniello A., and Scorza R. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand. J. Rheumatol. 35 (2006) 468-471
5. Black L.J., Sato M., Rowley E.R., Magee D.E., Bekele A., Williams D.C., Cullinan G.J., Bendele R., Kauffman R.F., Bensch W.R., Frolik C.A., Termine J.D., and Bryant H.U. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93 (1994) 63-69
6. Bracamonte M.P., Rud K.S., and Miller V.M. Mechanism of raloxifene-induced relaxation in femoral veins depends on ovarian hormonal status. J. Cardiovasc. Pharmacol. 39 (2002) 704-713
7. 2+ influx. J. Pharmacol. Exp. Ther. 312 (2005) 1266-1271
8. Chan Y.C., Leung F.P., Yao X., Lau C.W., Vanhoutte P.M., and Huang Y. Raloxifene modulates pulmonary vascular reactivity in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 49 (2007) 355-361
9. 2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin. Exp. Pharmacol. Physiol. 26 (1999) 707-715
10. De, and Marco T. Pulmonary arterial hypertension and women. Cardiol. Rev. 14 (2006) 312-318
11. Esqueda M.E., Craig T., and Hinojosa-Laborde C. Effect of ovariectomy on renal estrogen receptor-α and estrogen receptor-β in young salt-sensitive and -resistant rats. Hypertension 50 (2007) 768-772
12. Farhat M.Y., Chen M.F., Bhatti T., Iqbal A., Cathapermal S., and Ramwell P.W. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br. J. Pharmacol. 110 (1993) 719-723
13. A receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br. J. Pharmacol. 114 (1995) 925-930
14. Goldenthal E.I., D'Aguanno W., and Lynch J.F. Hormonal modification of the sex differences following monocrotaline administration. Toxicol. Appl. Pharmacol. 6 (1964) 434-441
15. Hill N.S., Warburton R.R., Pietras L., and Klinger J.R. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J. Appl. Physiol. 83 (1997) 1209-1215
16. Ichikawa K.I., Hidai C., Okuda C., Kimata S.I., Matsuoka R., Hosoda S., Quertermous T., and Kawana M. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J. Am. Coll. Cardiol. 27 (1996) 1286-1291
17. A receptor blockade. Clin. Sci. 105 (2003) 647-653
18. Jazbutyte V., Hu K., Kruchten P., Bey E., Maier S.K.G., Fritzemeier K.H., Prelle K., Hegele-Hartung C., Hartmann R.W., Neyses L., Ertl G., and Pelzer T. Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension 48 (2006) 579-586
19. Jazbutyte V., Arias-Loza P.A., Hu K., Widder J., Govindaraj V., von Poster-Klein C., Bauersachs J., Fritzemeier K.H., Hegele-Hartung C., Neyses L., Ertl G., and Pelzer T. Ligand-dependent activation of ERβ lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc. Res. 77 (2008) 774-781
20. Kasahara Y., Kiyatake K., Tatsumi K., Sugito K., Kakusaka I., Yamagata S., Ohmori S., Kitada M., and Kuriyama T. Bioactivation of monocrotaline by P-450 3A in rat liver. J. Cardiovasc. Pharmacol. 30 (1997) 124-129
21. Lahm T., Patel K.M., Crisostomo P.R., Markel T.A., Wang M., Herring C., and Meldrum D.R. Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am. J. Physiol. 293 (2007) E865-E871
22. Lahm T., Crisostomo P.R., Markel T.A., Wang M., Weil B.R., Novotny N.M., and Meldrum D.R. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit. Care Med. 36 (2008) 2174-2183
23. Leung F.P., Tsang S.Y., Wong C.M., Yung L.M., Chan Y.C., Leung H.S., Yao X., and Huang Y. Raloxifene, tamoxifen and vascular tone. Clin. Exp. Pharmacol. Physiol. 34 (2007) 809-813
24. Matsumura Y., Ikegawa R., Takaoka M., and Morimoto S. Conversion of porcine big endothelin by an extract from the porcine aortic endothelial cells. Biochem. Biophys. Res. Commun. 167 (1990) 203-210
25. Miller V.M., and Duckles S.P. Vascular actions of estrogens: functional implications. Pharmacol. Rev. 60 (2008) 210-241
26. Miyauchi T., Yorikane R., Sakai S., Sakurai T., Okada M., Nishikibe M., Yano M., Yamaguchi I., Sugishita Y., and Goto K. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ. Res. 73 (1993) 887-897
27. B receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension. J. Cardiovasc. Pharmacol. 44 (2004) 187-191
28. B receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats. Eur. J. Pharmacol. 496 (2004) 159-165
29. Ohkuma S., Ohkita M., Kawabata E., Hiramatsu A., Nishida M., and Matsumura Y. Raloxifene regulates endothelin-1 gene expression through the AMPK-induced NO production in cultured pulmonary artery endothelial cells. J. Pharmacol. Sci. 106 Suppl.I (2008) 214pp.
30. Ogita H., Node K., Liao Y., Ishikura F., Beppu S., Asanuma H., Sanada S., Takashima S., Minamino T., Hori M., and Kitakaze M. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 43 (2004) 237-242
31. Oviedo P.J., Hermenegildo C., and Cano A. Raloxifene increases the capacity of serum to promote prostacyclin release human endothelial cells: implication of COX-1 and COX-2. Menopause 11 (2004) 430-437
32. Packer C.S., Johnson T.C., Vijay P., Sharp T.G., Shannon D.J., Tighe S.M., and Chukwu H.V.N. Gender differences in pulmonary arterial reactivity to dilatory agonists in pulmonary hypertension. J. Gend. Specif. Med. 6 (2003) 30-38
33. Paquette A., Wang D., Gauthier M.S., Prud'homme D., Jankowski M., Gutkowska J., and Lavoie J.M. Specific adaptations of estrogen receptor α and β transcripts in liver and heart after endurance training in rats. Mol. Cell. Biochem. 306 (2007) 179-187
34. Rabinovitch M., Gamble W.J., Miettinen O.S., and Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am. J. Physiol. 240 (1981) H62-H72
35. Resta T.C., Kanagy N.L., and Walker B.R. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am. J. Physiol. 280 (2001) L88-L97
36. Saitta A., Altavilla D., Cucinotta D., Morabito N., Frisina N., Corrado F., D'Anna R., Lasco A., Squadrito G., Gaudio A., Cancellieri F., Arcoraci V., and Squadrito F. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1512-1519
37. Scorza R., Caronni M., Bazzi S., Nador F., Beretta L., Antonioli R., Origgi L., Ponti A., Marchini M., and Vanoli M. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann. N. Y. Acad. Sci. 966 (2002) 238-246
38. Shaw L., Taggart M., and Austin C. Effects of the oestrous cycle and gender on acute vasodilatory responses of isolated pressurized rat mesenteric arteries to 17β-oestradiol. Br. J. Pharmacol. 132 (2001) 1055-1062
39. Serock M.R., Wells A.K., and Khalil R.A. Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent. Pat. Cardiovasc. Drug. Discov. 3 (2008) 165-186
40. Shohet R.V., Kisanuki Y.Y., Zhao X.S., Siddiquee Z., Franco F., and Yanagisawa M. Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2088-2093
41. Shubeita H.E., McDonough P.M., Harris A.N., Knowlton K.U., Glembotski C.C., Brown J.H., and Chien K.R. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. J. Biol. Chem. 265 (1990) 20555-20562
42. Simonneau G., Galiè N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., Gibbs S., Lebrec D., Speich R., Beghetti M., Rich S., and Fishman A. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43 (2004) 5S-12S
43. Smith A.M., Jones1 R.D., and Channer K.S. The influence of sex hormones on pulmonary vascular reactivity: possible vasodilator therapies for the treatment of pulmonary hypertension. Curr. Vasc. Pharmacol. 4 (2006) 9-15
44. Sudhir K., and Komesaroff P.A. Cardiovascular actions of estrogen in men. J. Clin. Endocrinol. Metab. 84 (1999) 3411-3415
45. Tofovic S.P., Zhang X., Jackson E.K., Dacic S., and Petrusevska G. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vasc. Pharmacol. 45 (2006) 358-367
46. Tostes R.C., Fortes Z.B., Callera G.E., Montezano A.C., Touyz R.M., Webb R.C., and Carvalho M.H.C. Endothelin, sex and hypertension. Clin. Sci. 114 (2008) 85-97
47. Wassmann S., Laufs U., Stamenkovic D., Linz W., Stasch J.P., Ahlbory K., Rösen R., Böhm M., and Nickenig G. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 105 (2002) 2083-2091
48. Yamazaki T., Komuro I., Kudoh S., Zou Y., Shiojima I., Hiroi Y., Mizuno T., Maemura K., Kurihara H., Aikawa R., Takano H., and Yazaki Y. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J. Biol. Chem. 271 (1996) 3221-3228
49. Yang L.L., Gros R., Kabir M.G., Sadi A., Gotlieb A.I., Husain M., and Stewart D.J. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 109 (2004) 255-261
50. Zoma W.D., Baker R.S., Mershon J.L., and Clark K.E. Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep. Am. J. Physiol. 291 (2006) H1216-H1225